The Markers of Glutamate Metabolism in Peripheral Blood Mononuclear Cells and Neurological Complications in Lung Cancer Patients

Abstract

Objective. To evaluate the involvement of glutamate metabolism in peripheral blood mononuclear cells (PBMC) in the development of neurological complications in lung cancer and during chemotherapy. Methods. The prospective study included 221 lung cancer patients treated with chemotherapeutics. Neurological status and cognitive functions were evaluated at baseline and after 6-month follow-up. Glutamate level, the activities of glutaminase- (GLS-) glutamate synthetizing enzyme, glutamate dehydrogenase (GDH), and glutamate decarboxylase catalyzing glutamate degradation were analyzed in PBMC and in sera of lung cancer patients by means of spectrophotometric and colorimetric methods. Results. Chemotherapy of lung neoplasms induced increase of glutamate content in PBMC and its concentration in serum increased the activity of GDH in PBMC and decreased activity of glutaminase in PBMC. The changes in glutamate metabolism markers were associated with initial manifestation of neurological deficit in lung cancer patients and with new symptoms, which appear as a complication of chemotherapy. Moreover, the analyzed parameters of glutamate control correlated with a spectrum of cognitive functions measures in lung cancer patients. Conclusion. We have demonstrated dysregulation in glutamate and glutamate metabolism controlling enzymes as promising indicators of risk for chemotherapy-induced neurological complications in lung cancer patients with particular emphasis on cognitive impairment.

iTRAQ‐Based Quantitative Proteomics Approach Identifies Novel Diagnostic Biomarkers That Were Essential for Glutamine Metabolism and Redox Homeostasis for Gastric Cancer

“…A growing body of evidence shows that GLS1 was highly expressed in a various of human tumor cells such as triple‐negative breast cancer, lung cancer, oral squamous cell carcinoma, human hepatoblastoma, acute myeloid leukemia. and gastroenteropancreatic cancer . Over expression of GLS1 presented high proliferation rate in tumors such as gliomas and non‐small‐cell lung cancer .…”

5-Fluorouracil impairs attention and dopamine release in rats

“…In previous work, we found that rats treated with 5-FU lack inhibitory control [12]. Additionally, treatment with carboplatin, another commonly used chemotherapeutic agent associated with chemobrain [26], not only impaired working memory [12], but also decreased neurotransmitter release [19]. The current study tested effects of 5-FU on attention, a fundamental component of EF.…”

Neurotransmitter signalling via NMDA receptors leads to decreased T helper type 1‐like and enhanced T helper type 2‐like immune balance in humans

“…47 Physical interaction of glutamate and T cells has been demonstrated using radio-labelled glutamate. 48 In addition to elevated glutamate levels in white brain matter of patients with multiple sclerosis, 49 glutamate levels were found to be elevated in plasma of patients with several immune diseases, including HIV infection, 50,51 cancer, 52,53 and rheumatoid arthritis. 54,55 Here, glutamate, NMDA and QA were all used to examine NMDA-R function in peripheral human CD4 + T cells.…”